NCT00641381View on ClinicalTrials.gov

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 10, 2000

Primary Completion Date

February 27, 2026

Study Completion Date

February 27, 2026

Conditions
Lymphoma
Interventions
DRUG

carmustine

150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion

DRUG

cyclophosphamide

100 mg/kg on day -2 prior to stem cell reinfusion

DRUG

etoposide

60 mg/kg on day -4 prior to stem cell reinfusion

OTHER

pharmacological study

Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion

PROCEDURE

autologous hematopoietic stem cell transplantation

Reinfusion of autologous stem cells

PROCEDURE

peripheral blood stem cell transplantation

Reinfusion of autologous stem cells

Trial Locations (1)

91010-3000

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER